Skip to content
HowShorted

ABEONA THERAPEUTICS INC. short interest in 2025

In 2025, ABEONA THERAPEUTICS INC.'s disclosed short interest ran from 6.13% of shares outstanding on 15 Jan 2025 to 24.44% on 31 Dec 2025, a change of +18.31 percentage points. The year's high was 25.83% on 15 Dec 2025 and its low 4.56% on 31 Mar 2025, averaging 14.46% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 14.03 days on 31 Dec 2025. Full history: ABEONA THERAPEUTICS INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for ABEONA THERAPEUTICS INC. in 2025

2025 in figures

Start of year
6.13% (15 Jan 2025)
End of year
24.44% (31 Dec 2025)
Change
+18.31 pp
High
25.83% (15 Dec 2025)
Low
4.56% (31 Mar 2025)
Average
14.46%
Highest days to cover
14.03 (31 Dec 2025)
SEC filings marked
9

Every report in 2025

ABEONA THERAPEUTICS INC. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20256.13%8.15
31 Jan 20255.70%9.14
14 Feb 20255.67%9.03
28 Feb 20255.80%10.09
14 Mar 20254.92%6.04
31 Mar 20254.56%4.2010-K filed, results (8-K)
15 Apr 20255.69%2.75
30 Apr 202511.24%1.27
15 May 202512.14%2.8110-Q filed, results (8-K)
30 May 202512.38%4.56
13 Jun 202513.32%7.96
30 Jun 202517.09%5.54
15 Jul 202517.47%10.89results (8-K)
31 Jul 202517.34%12.89
15 Aug 202517.19%12.3110-Q filed, results (8-K)
29 Aug 202517.61%13.22
15 Sep 202517.03%10.59
30 Sep 202516.82%8.31
15 Oct 202517.92%8.67
31 Oct 202520.18%6.35
14 Nov 202525.08%3.9110-Q filed, results (8-K)
28 Nov 202525.49%8.04
15 Dec 202525.83%10.22
31 Dec 202524.44%14.03

See also: ABEONA THERAPEUTICS INC.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.